Paul Moss

InstitutionUniversity of Birmingham
AddressBirmingham
United Kingdom
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 15 Covid-19 publications, with a maximum of 3 publications in June 2021 and July 2021 and August 2021
    All Publications
    Bar chart showing 138 publications over 21 distinct years, with a maximum of 13 publications in 2015 and 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Parry H, Bruton R, Stephens C, Brown K, Amirthalingam G, Otter A, Hallis B, Zuo J, Moss P. Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people. Immun Ageing. 2021 Aug 20; 18(1):34. PMID: 34416887.
      Citations: 5     
    2. Tut G, Lancaster T, Krutikov M, Sylla P, Bone D, Kaur N, Spalkova E, Bentley C, Amin U, Jadir AT, Hulme S, Butler MS, Ayodele M, Bruton R, Shrotri M, Azmi B, Fuller C, Irwin-Singer A, Hayward A, Copas A, Shallcross L, Moss P. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. Lancet Healthy Longev. 2021 Sep; 2(9):e544-e553. PMID: 34430954.
      Citations: 3     
    3. Parry H, Bruton R, Tut G, Ali M, Stephens C, Greenwood D, Faustini S, Hughes S, Huissoon A, Meade R, Brown K, Amirthalingam G, Otter A, Hallis B, Richter A, Zuo J, Moss P. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. Lancet Healthy Longev. 2021 Sep; 2(9):e554-e560. PMID: 34401865.
      Citations: 4     
    4. Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, Otter A, McSkeane T, Rolfe H, Faustini S, Wall N, Hillmen P, Pratt G, Paneesha S, Zuo J, Richter A, Moss P. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021 07 30; 11(7):136. PMID: 34330895.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    5. Ebanks D, Faustini S, Shields A, Parry H, Moss P, Plant T, Richter A, Drayson M. Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays. J Infect. 2021 Oct; 83(4):e18-e20. PMID: 34324939.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    6. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, Aiano F, Amin-Chowdhury Z, Hoschler K, Brooks T, Taylor S, Hewson J, Hallis B, Stapley L, Borrow R, Linley E, Ahmad S, Parker B, Horsley A, Amirthalingam G, Brown K, Ramsay ME, Ladhani S, Moss P. Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021 Jul; 22(7):928. PMID: 34017126.
      Citations: 2     Fields:    
    7. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, Fuller C, Irwin-Singer A, Davies D, Tut G, Lopez Bernal J, Moss P, Hayward A, Copas A, Shallcross L. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 11; 21(11):1529-1538. PMID: 34174193.
      Citations: 31     Fields:    Translation:HumansPHPublic Health
    8. Sethi S, Kumar A, Mandal A, Shaikh M, Hall CA, Kirk JMW, Moss P, Brookes MJ, Basu S. The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy. BMJ Open. 2021 06 15; 11(6):e048856. PMID: 34130964.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    9. Krutikov M, Palmer T, Tut G, Fuller C, Shrotri M, Williams H, Davies D, Irwin-Singer A, Robson J, Hayward A, Moss P, Copas A, Shallcross L. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. Lancet Healthy Longev. 2021 Jun; 2(6):e362-e370. PMID: 34104901.
      Citations: 10     
    10. Sethi S, Kumar A, Mandal A, Shaikh M, Hall CA, Kirk JMW, Moss P, Brookes MJ, Basu S. The UPTAKE study: implications for the future of COVID-19 vaccination trial recruitment in UK and beyond. Trials. 2021 Apr 20; 22(1):296. PMID: 33879208.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    11. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, Aiano F, Amin-Chowdhury Z, Hoschler K, Brooks T, Taylor S, Hewson J, Hallis B, Stapley L, Borrow R, Linley E, Ahmad S, Parker B, Horsley A, Amirthalingam G, Brown K, Ramsay ME, Ladhani S, Moss P. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021 05; 22(5):620-626. PMID: 33674800.
      Citations: 74     Fields:    Translation:HumansCells
    12. Subbarao S, Warrener LA, Hoschler K, Perry KR, Shute J, Whitaker H, O'Brien M, Baawuah F, Moss P, Parry H, Ladhani SN, Ramsay ME, Brown KE, Amirthalingam G. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Euro Surveill. 2021 03; 26(12). PMID: 33769252.
      Citations: 11     Fields:    Translation:Humans
    13. Krutikov M, Palmer T, Donaldson A, Lorencatto F, Forbes G, Copas A, Robson J, Hopkins S, Moss P, Farrar J, Hayward A, Shallcross L. Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI). Wellcome Open Res. 2020; 5:232. PMID: 33564722.
      Citations: 5     
    14. Glynn JR, Moss PAH. Systematic analysis of infectious disease outcomes by age shows lowest severity in school-age children. Sci Data. 2020 10 15; 7(1):329. PMID: 33057040.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    15. Moss P. "The ancient and the new": is there an interaction between cytomegalovirus and SARS-CoV-2 infection? Immun Ageing. 2020; 17:14. PMID: 32501397.
      Citations: 17     
    Moss's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (204)
    Explore
    _
    Co-Authors (105)
    Explore
    _
    Similar People (60)
    Explore
    _